Elevation Oncology
ELEV
ELEV was delisted on the 22nd of July, 2025.
1 hedge funds and large institutions have $720 invested in Elevation Oncology in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 64 closing their positions.
49.88% less ownership
Funds ownership: 49.88% → 0% (-50%)
98% less funds holding
Funds holding: 65 → 1 (-64)
100% less capital invested
Capital invested by funds: $10.8M → $720 (-$10.8M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 64
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$2.2M |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$2.16M |
| 3 |
ACM
Aisling Capital Management
New York
|
-$1.04M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$828K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$529K |
ELEV Hedge Fund Activity: Q3 2025 in Review
1 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q3 2025, worth a combined $720 — down 100% from $10.8M a quarter earlier.
Sellers outnumbered buyers: 64 funds closed out of ELEV and 0 opened new positions — a net loss of 64 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Frazier Life Sciences Management, exiting entirely with an estimated $2.2M sold.
- 1 institutional investor held Elevation Oncology (ELEV) as of Q3 2025, down from 65 in Q2 2025.
- Funds reported $720 of Elevation Oncology stock for Q3 2025, down 100% quarter-over-quarter.
- 0 funds opened new Elevation Oncology positions in Q3 2025 and 64 closed out, a net change of -64 holders.
- The largest Elevation Oncology seller in Q3 2025 was Frazier Life Sciences Management, an estimated $2.2M sold.
Based on aggregated 13F filings for Q3 2025.